A human neutralizing antibody or antigen-binding fragment thereof and its application
By developing specific human neutralizing antibodies or antigen-binding fragments, the problem of restricted neutralization activity of the new coronavirus mutant strain has been solved, and a variety of new coronavirus viruses, including the original SARS-CoV-2 strain and multiple mutant poisons have been achieved. Effective neutralization of the strain, especially the efficient neutralization of the Delta and Omicron variants, has broad-spectrum and clinical application value.
Patent Information
- Application Number
- CN202211110370.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-03-28
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2042-03-28
AI Technical Summary
The existing new coronavirus neutralizing antibodies are limited in neutralizing activity against the new coronavirus mutant strain, especially the Omicron mutant strain, which leads to a decrease in neutralization ability and cannot effectively prevent and treat infections of multiple mutant strains.
Develop a human neutralizing antibody or antigen-binding fragment thereof, containing specific heavy and light chain variable region amino acid sequences, capable of effectively neutralizing SARS-CoV-2 original strains and multiple variant strains (such as Beta) , Delta, Omicron) new coronaviruses, including Alpha, Beta, Gamma, Lambda, Kappa, Delta and Omicron.
This neutralizing antibody has good neutralization activity on the original strain of the new coronavirus SARS-CoV-2 and various variant strains, especially on the harmful Delta and Omicron variants, with IC50≤0.04ug /ml can effectively inhibit fake virus and real virus infection, and has broad-spectrum and clinical application value.
Smart Images

Figure SMS_2 
Figure HDA0003843816960000011 
Figure HDA0003843816960000012
Abstract
Description
[0001] This invention is a divisional application of the Chinese application with an application date of March 28, 2022, application number 202210313522.1, and the name of the invention being “A human neutralizing antibody or its antigen-binding fragment and its application”. Technical Field
[0002] The present invention relates to the field of biomedicine, and specifically to a human neutralizing antibody or an antigen-binding fragment thereof and applications thereof, and more specifically to a human neutralizing antibody or an antigen-binding fragment thereof, a polypeptide, a polynucleotide, a nucleic acid construct, an expression vector, a transformed cell, a pharmaceutical composition that binds to a coronavirus S protein, and applications thereof in the preparation of drugs for preventing, treating, detecting or diagnosing novel coronavirus infection. Background Art
[0003] Coronavirus disease 2019 (COVID-19) is caused by a novel coronavirus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The S protein of SARS-CoV-2 mediates viral membrane fusion and receptor recognition. Among them, the S1 subunit located in the N-terminal region of the spike (S) glycoprotein is responsible for viral attachment, its RBD directly binds to the ACE2 receptor on the host cell, and the S2 subunit (C-terminal) is responsible for membrane fusion. Currently, most SARS-CoV-2 vaccines under development target the spike (S) glycoprotein and have the ability to induce high levels of neutralizing antibodies (NAbs) targeting the S protein or RBD. However, considering the long-term nature of clinical trials and the uncertainty of the effectiveness of vaccines in humans, the study of SARS-CoV-2 neutralizing antibodies with expected efficacy and safety is also key to the treatment strategy for COVID-19. At present, it has been reported that a variety of SARS-CoV-2 specific neutralizing antibody drugs have been approved or are under clinical research.
[0004] Most of the existing neutralizing antibodies against the new coronavirus are traditional monoclonal antibodies isolated from the bodies of patients who have recovered from new coronavirus infection. Since the neutralizing antibodies isolated from the serum of recovered patients are affected by factors such as the mutation of the virus strain, the broad-spectrum neutralizing activity of the isolated neutralizing antibodies is often limited.
[0005] However, SARS-CoV-2 is an RNA virus with a high mutation rate of amino acids in its surface protein. Many mutant strains have been reported, such as Delta, Lambda, Kappa, etc., and a new mutant strain, Omicron, has recently appeared. Most of these mutant strains are more contagious, have stronger replication ability, have higher viral loads, and can evade the neutralization ability of neutralizing antibodies. At present, the neutralizing antibody ability of antibody drugs for the recently emerged Omicron (B.1.1.529) mutant strain has decreased significantly, so it is urgent to screen for a broad-spectrum neutralizing antibody that can prevent known and future variant infections. Summary of the invention
[0006] Object of the Invention
[0007] The purpose of the present invention is to provide a human neutralizing antibody or an antigen-binding fragment thereof and its application, more specifically, to a human neutralizing antibody or an antigen-binding fragment thereof, a polypeptide, a polynucleotide, a nucleic acid construct, an expression vector, a transformed cell, a pharmaceutical composition, and their application in the preparation of a drug for preventing or treating or detecting or diagnosing novel coronavirus infection. The human neutralizing antibody of the present invention can effectively neutralize a variety of novel coronavirus variants including the original strain (WT) of the novel coronavirus SARS-CoV-2, the variant strain Beta (B.1.351), the variant strain Delta (B.1.617.2), the variant strain Omicron (B.1.1.529), etc.
[0008] Solution
[0009] To achieve the above object, the present invention provides the following technical solutions:
[0010] In a first aspect, the present invention provides a humanized neutralizing antibody or an antigen-binding fragment thereof that binds to a coronavirus S protein, comprising a heavy chain variable region and / or a light chain variable region,
[0011] The heavy chain variable region comprises:
[0012] (I) HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:1 (i.e., SNYMH), SEQ ID NO:2 (i.e., VLYAGGSAFYADSVKG) and SEQ ID NO:3 (i.e., CARGLGDYLDSW), respectively; or HCDR1, HCDR2 and HCDR3 having 1, 2 or 3 amino acid differences from the amino acid sequences as shown in SEQ ID NO:1 (i.e., SNYMH), SEQ ID NO:2 (i.e., VLYAGGSAFYADSVKG) and SEQ ID NO:3 (i.e., CARGLGDYLDSW), respectively; or
[0013] (II) HCDR1, HCDR2 and HCDR3 whose amino acid sequences are respectively as shown in SEQ ID NO:11 (i.e., GFSFITY), SEQ ID NO:12 (i.e., SSNILS) and SEQ ID NO:13 (i.e., CARTRSRSVRNCTSATCPVDAFDLW); or HCDR1, HCDR2 and HCDR3 which have 1, 2 or 3 amino acid differences from the amino acid sequences shown in SEQ ID NO:11 (i.e., GFSFITY), SEQ ID NO:12 (i.e., SSNILS) and SEQ ID NO:13 (i.e., CARTRSRSVRNCTSATCPVDAFDLW); or
[0014] (III) HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:21 (i.e., TSGVSVG), SEQ ID NO:22 (i.e., LIYWDDDKRYSPSLTS) and SEQ ID NO:23 (i.e., PRYYGDSSGYYWI), respectively; or HCDR1, HCDR2 and HCDR3 having 1, 2 or 3 amino acid differences from the amino acid sequences as shown in SEQ ID NO:21 (i.e., TSGVSVG), SEQ ID NO:22 (i.e., LIYWDDDKRYSPSLTS) and SEQ ID NO:23 (i.e., PRYYGDSSGYYWI), respectively;
[0015] The light chain variable region comprises:
[0016] (I) LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:4 (i.e., RASQGIGSWLA), SEQ ID NO:5 (i.e., AASTLQS) and SEQ ID NO:6 (i.e., QQANSVLALT), respectively; or LCDR1, LCDR2 and LCDR3 having 1, 2 or 3 amino acid differences from the amino acid sequences as shown in SEQ ID NO:4 (i.e., RASQGIGSWLA), SEQ ID NO:5 (i.e., AASTLQS) and SEQ ID NO:6 (i.e., QQANSVLALT), respectively; or
[0017] (II) LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:14 (i.e., RSSQSLLRSNGYNYLD), SEQ ID NO:15 (i.e., LGSNRAS) and SEQ ID NO:16 (i.e., MQALQTPYT), respectively; or LCDR1, LCDR2 and LCDR3 having 1, 2 or 3 amino acid differences from the amino acid sequences as shown in SEQ ID NO:14 (i.e., RSSQSLLRSNGYNYLD), SEQ ID NO:15 (i.e., LGSNRAS) and SEQ ID NO:16 (i.e., MQALQTPYT), respectively; or
[0018] (III) HCDR1, HCDR2 and HCDR3 whose amino acid sequences are shown in SEQ ID NO:24 (i.e., SGDALPKQYAY), SEQ ID NO:25 (i.e., KTSERPS) and SEQ ID NO:26 (i.e., QSADSSGFYV), respectively; or HCDR1, HCDR2 and HCDR3 having 1, 2 or 3 amino acid differences from the amino acid sequences shown in SEQ ID NO:24 (i.e., SGDALPKQYAY), SEQ ID NO:25 (i.e., KTSERPS) and SEQ ID NO:26 (i.e., QSADSSGFYV), respectively.
[0019] The coronavirus of the present invention mainly refers to the new coronavirus SARS-CoV-2, and may also have neutralizing activity against other coronaviruses. The S protein in the present invention mainly refers to the S1 antigen of the new coronavirus SARS-CoV-2.
[0020] In some embodiments, the human neutralizing antibody or antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain variable region and / or a light chain variable region,
[0021] The heavy chain variable region comprises:
[0022] (I) HCDR1, HCDR2 and HCDR3 with amino acid sequences as shown in SEQ ID NO:1 (i.e., SNYMH), SEQ ID NO:2 (i.e., VLYAGGSAFYADSVKG) and SEQ ID NO:3 (i.e., CARGLGDYLDSW), respectively; or
[0023] (II) HCDR1, HCDR2 and HCDR3 whose amino acid sequences are shown in SEQ ID NO:11 (i.e., GFSFITY), SEQ ID NO:12 (i.e., SSNILS) and SEQ ID NO:13 (i.e., CARTRSRSVRNCTSATCPVDAFDLW), respectively; or
[0024] (III) HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:21 (i.e., TSGVSVG), SEQ ID NO:22 (i.e., LIYWDDDKRYSPSLTS) and SEQ ID NO:23 (i.e., PRYYGDSSGYYWI), respectively;
[0025] The light chain variable region comprises:
[0026] (I) LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:4 (i.e., RASQGIGSWLA), SEQ ID NO:5 (i.e., AASTLQS) and SEQ ID NO:6 (i.e., QQANSVLALT), respectively; or
[0027] (II) LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:14 (i.e., RSSQSLLRSNGYNYLD), SEQ ID NO:15 (i.e., LGSNRAS) and SEQ ID NO:16 (i.e., MQALQTPYT), respectively; or
[0028] (III) HCDR1, HCDR2 and HCDR3 whose amino acid sequences are shown in SEQ ID NO: 24 (i.e., SGDALPKQYAY), SEQ ID NO: 25 (i.e., KTSERPS) and SEQ ID NO: 26 (i.e., QSADSSGFYV), respectively.
[0029] In some embodiments, the human neutralizing antibody or antigen-binding fragment thereof comprises:
[0030] (I) a heavy chain variable region having an amino acid sequence having HCDR1, HCDR2 and HCDR3 as shown in SEQ ID NO:1 (i.e., SNYMH), SEQ ID NO:2 (i.e., VLYAGGSAFYADSVKG) and SEQ ID NO:3 (i.e., CARGLGDYLDSW), respectively; and a light chain variable region having an amino acid sequence having LCDR1, LCDR2 and LCDR3 as shown in SEQ ID NO:4 (i.e., RASQGIGSWLA), SEQ ID NO:5 (i.e., AASTLQS) and SEQ ID NO:6 (i.e., QQANSVLALT), respectively; or
[0031] (II) a heavy chain variable region having an amino acid sequence of HCDR1, HCDR2 and HCDR3 as shown in SEQ ID NO:11 (i.e., GFSFITY), SEQ ID NO:12 (i.e., SSNILS) and SEQ ID NO:13 (i.e., CARTRSRSVRNCTSATCPVDAFDLW), respectively; and a light chain variable region having an amino acid sequence of LCDR1, LCDR2 and LCDR3 as shown in SEQ ID NO:14 (i.e., RSSQSLLRSNGYNYLD), SEQ ID NO:15 (i.e., LGSNRAS) and SEQ ID NO:16 (i.e., MQALQTPYT), respectively; or
[0032] (III) a heavy chain variable region having an amino acid sequence having HCDR1, HCDR2 and HCDR3 as shown in SEQ ID NO:21 (i.e., TSGVSVG), SEQ ID NO:22 (i.e., LIYWDDDKRYSPSLTS) and SEQ ID NO:23 (i.e., PRYYGDSSGYYWI), respectively; and a light chain variable region having an amino acid sequence having LCDR1, LCDR2 and LCDR3 as shown in SEQ ID NO:24 (i.e., SGDALPKQYAY), SEQ ID NO:25 (i.e., KTSERPS) and SEQ ID NO:26 (i.e., QSADSSGFYV), respectively.
[0033] In some embodiments, the human neutralizing antibody or antigen-binding fragment thereof comprises a heavy chain variable region and / or a light chain variable region,
[0034] (I) the heavy chain variable region comprises the amino acid sequence as set forth in SEQ ID NO:7, or an amino acid sequence that has at least 95%, 96%, 97%, 98% or 99% sequence identity to the amino acid sequence as set forth in SEQ ID NO:7; and the light chain variable region comprises the amino acid sequence as set forth in SEQ ID NO:8, or an amino acid sequence that has at least 95%, 96%, 97%, 98% or 99% sequence identity to the amino acid sequence as set forth in SEQ ID NO:8; or
[0035] (II) the heavy chain variable region comprises the amino acid sequence as set forth in SEQ ID NO:17, or an amino acid sequence that has at least 95%, 96%, 97%, 98% or 99% sequence identity to the amino acid sequence as set forth in SEQ ID NO:17; and the light chain variable region comprises the amino acid sequence as set forth in SEQ ID NO:18, or an amino acid sequence that has at least 95%, 96%, 97%, 98% or 99% sequence identity to the amino acid sequence as set forth in SEQ ID NO:18; or
[0036] (III) the heavy chain variable region comprises the amino acid sequence as shown in SEQ ID NO:27, or an amino acid sequence that has at least 95%, 96%, 97%, 98% or 99% sequence identity to the amino acid sequence as shown in SEQ ID NO:27; and the light chain variable region comprises the amino acid sequence as shown in SEQ ID NO:28, or an amino acid sequence that has at least 95%, 96%, 97%, 98% or 99% sequence identity to the amino acid sequence as shown in SEQ ID NO:28.
[0037] In some embodiments, the human neutralizing antibody or antigen-binding fragment thereof comprises a heavy chain variable region and / or a light chain variable region, (I) the heavy chain variable region comprises the amino acid sequence shown in SEQ ID NO:7, and the light chain variable region comprises the amino acid sequence shown in SEQ ID NO:8, and the antibody having the amino acid sequences shown in SEQ ID NO:7 and SEQ ID NO:8, respectively, is named YB9-258; or
[0038] (II) the heavy chain variable region comprises the amino acid sequence shown in SEQ ID NO: 17, and the light chain variable region comprises the amino acid sequence shown in SEQ ID NO: 18, and the antibody having the amino acid sequences shown in SEQ ID NO: 17 and SEQ ID NO: 18, respectively, is named YB13-292; or
[0039] (III) the heavy chain variable region comprises the amino acid sequence shown in SEQ ID NO:27; and the light chain variable region comprises the amino acid sequence shown in SEQ ID NO:28. The antibody having the amino acid sequences shown in SEQ ID NO:27 and SEQ ID NO:28, respectively, is named YB13-208.
[0040] In the above example, the amino acid sequence of the heavy chain variable region of the neutralizing antibody YB9-258 shown in SEQ ID NO:7 is as follows:
[0041] EVQLVESGGGLIQPGGSLRLSCAASGLTVS SNYMH WVRQAPGKGLEWVS VLYAGGSAFYADSVKG RFT ISRNNSKNTLYLQMNSLRAEDTAIYY CARGLGDYLDSW GQGTLVTVSS ; Among them, the underlined parts are the framework regions FR1-4 of the heavy chain variable region, and the black parts are HCDR1, HCDR2 and HCDR3 of the heavy chain variable region.
[0042] In the above example, the amino acid sequence of the light chain variable region of the neutralizing antibody YB9-258 as shown in SEQ ID NO:8 is as follows:
[0043] DIQMTQSPSSVSASVGDRVTITC RASQGIGSWLA WYQQKPGKAPQLLIY AASTLQS GVPPRFSGSGSG TDFTLTITSLQPEDFASYYC QQANSVLALT FGGGTKVEIK ; Among them, the underlined parts are the framework regions FR1-4 of the light chain variable region, and the black parts are LCDR1, LCDR2 and LCDR3 of the heavy chain variable region.
[0044] In the above embodiment, the amino acid sequence of the heavy chain variable region of the neutralizing antibody YB13-292 shown in SEQ ID NO: 17 is as follows:
[0045] EVQLVESGGGLVKPGGSLRLSCAAS GFSFITY NMNWVRQAPGKGLEWVSSI SSNILS STSYIYYADSVKGRFTISRDDAANSLFLQMNSLRVEDTAQYY CARTRSRSVRNCTSATCPVDAFDLW GQGTMVIVSS; wherein, the underlined parts are the framework regions FR1-4 of the heavy chain variable region, and the black parts are the HCDR1, HCDR2 and HCDR3 of the heavy chain variable region.
[0046] In the above example, the amino acid sequence of the light chain variable region of the neutralizing antibody YB13-292 as shown in SEQ ID NO: 18 is as follows:
[0047] DIVLTQSPLSLPVTPGEPASISC RSSQSLLRSNGYNYLD WYLQKPGQSPHLLIY LGSNRAS GVPDRFSGSGSGTDFTLKISRVEAEDVGVYYC MQALQTPYT FGQGTNLEIK; wherein, the underlined parts are the framework regions FR1-4 of the light chain variable region, and the black parts are LCDR1, LCDR2 and LCDR3 of the heavy chain variable region.
[0048] In the above embodiment, the amino acid sequence of the heavy chain variable region of the neutralizing antibody YB13-208 shown in SEQ ID NO: 27 is as follows:
[0049] QITLKESGPTLVKPTQTLTLTCTFSGLSLS TSGVSVG WIRQPPGKAPEWLA LIYWDDDKRYSPSLTS R LSITKDTSKNQVVLTMTNMDPVDTATYYCAH PRYYGDSSGYYWI WGQGTMVTVSS ; Among them, the underlined parts are the framework regions FR1-4 of the heavy chain variable region, and the black parts are HCDR1, HCDR2 and HCDR3 of the heavy chain variable region.
[0050] In the above embodiment, the amino acid sequence of the light chain variable region of the neutralizing antibody YB13-208 shown in SEQ ID NO: 28 is as follows:
[0051] SYELTQPPSVSVSPGQTARITC SGDALPKQYAYWYQQKPGQAPVVVMYKTSERPS GIPERFSGSSSGT TVTLTISGVQAEDEADYYC QSDSGFY FGTGTQVTVL ; Among them, the underlined parts are the framework regions FR1-4 of the light chain variable region, and the black parts are LCDR1, LCDR2 and LCDR3 of the heavy chain variable region.
[0052] In some embodiments, the human neutralizing antibody or its antigen-binding fragment, wherein the antigen-binding fragment is selected from Fab, Fab', Fab'-SH, Fv, scFv, F(ab')2, and diabody.
[0053] In the second aspect, the present invention provides a polypeptide comprising a sequence selected from SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:27 and / or SEQ ID NO:28; optionally, the polypeptide described in the second aspect has a sequence shown in SEQ ID NO:7 and / or SEQ ID NO:8; optionally, the polypeptide described in the second aspect has a sequence shown in SEQ ID NO:17 and / or SEQ ID NO:18; optionally, the polypeptide described in the second aspect has a sequence shown in SEQ ID NO:27 and / or SEQ ID NO:28.
[0054] In a third aspect, a polynucleotide is provided, which encodes the human neutralizing antibody or its antigen-binding fragment that binds to the coronavirus S protein.
[0055] Furthermore, the polynucleotide is DNA or mRNA.
[0056] Further, the polynucleotide has a nucleotide sequence such as SEQ ID NO:9 and / or SEQ ID NO:10; or the polynucleotide has a nucleotide sequence such as SEQ ID NO:19 and / or SEQ ID NO:20; or the polynucleotide has a nucleotide sequence such as SEQ ID NO:29 and / or SEQ ID NO:30.
[0057] In some embodiments, the polynucleotide has a nucleotide sequence such as SEQ ID NO:9 and SEQ ID NO:10; or the polynucleotide has a nucleotide sequence such as SEQ ID NO:19 and SEQ ID NO:20; or the polynucleotide has a nucleotide sequence such as SEQ ID NO:29 and SEQ ID NO:30.
[0058] The nucleotide sequence shown in SEQ ID NO: 9 corresponds to the amino acid sequence encoded by SEQ ID NO: 7. The nucleotide sequence shown in SEQ ID NO: 9 is as follows:
[0059] gaagtgcaac tagtggaaag tggtggtggt ctgatccagc ccggaggctc tctgcggctg 60
[0060] tcttgtgctg cttctggact caccgtgtcc tccaactaca tgcactgggt gcggcaagct 120
[0061] cctggcaagg gcctggaatg ggtctccgtg ctgtatgctg gcggctccgc cttctacgcc 180
[0062] gattctgtga aaggcagatt caccatctcc cgcaacaact ccaagaacac cctgtacctg 240
[0063] cagatgaata gcctgagagc cgaggacacc gccatctact actgcgccag aggcctgggc 300
[0064] gactacctgg actcctgggg ccagggcaca ctggtgaccg tgtctagc 348
[0065] The nucleotide sequence shown in SEQ ID NO: 10 corresponds to the amino acid sequence encoded by SEQ ID NO: 8. The nucleotide sequence shown in SEQ ID NO: 10 is as follows:
[0066] gatatccaaa tgactcaaag tccaagtagt gtcagcgcct ctgtgggcga cagagtgacc 60
[0067] atcacctgta gagccagcca gggcatcggc tcctggctgg cctggtacca gcagaaaccc 120
[0068] ggcaaggccc ctcagctgct gatctacgct gcttctacac tgcaatccgg cgtgcctcca 180
[0069] cggttctccg gatctggctc tggcaccgac ttcaccctga caatcacctc cctgcagcct 240
[0070] gaggattttg cttcctacta ctgccagcag gccaactccg tgctggctct caccttcggc 300
[0071] ggcggaacca aggtggaaat caag 324
[0072] The nucleotide sequence shown in SEQ ID NO: 19 corresponds to the amino acid sequence encoded by SEQ ID NO: 17. The nucleotide sequence shown in SEQ ID NO: 19 is as follows:
[0073] gaagtgcaac tagtggaaag tggtggtggt ctcgtgaagc ccggcggctc tctgcggctg 60
[0074] tcctgcgctg cttctggatt ttccttcatc acctacaaca tgaactgggt gcgccaagct 120
[0075] cctggcaagg gcctggagtg ggtcagctcc atctcctcca acatcctgtc ttctacatcc 180
[0076] tacatctact atgccgactc cgtgaaaggc agattcacca tctctcggga cgatgccgcc 240
[0077] aactccctgt tcctgcagat gaatagcctg agagtggaag atacagctca gtactactgc 300
[0078] gccagaacca gatccagatc tgtgcggaac tgcacctctg ccacctgtcc tgtggacgcc 360
[0079] ttcgacctgt ggggccaggg caccatggtg atcgtgtcca gc 402
[0080] The nucleotide sequence shown in SEQ ID NO:20 corresponds to the amino acid sequence encoded by SEQ ID NO:18. The nucleotide sequence shown in SEQ ID NO:20 is as follows:
[0081] gatatcgtgc taactcaaag tccactaagt ctgcctgtga ccccaggcga gcctgcttcc 60
[0082] atcagctgta gatcctctca gtctctgctg cggtccaacg gctacaacta cctggactgg 120
[0083] tatctccaga aacctggcca atctcctcac ctgctgatct acctgggctc caatcgggct 180
[0084] tctggagtcc ccgatagatt ctccggctct ggcagcggaa cagacttcac cctgaagatc 240
[0085] tccagagtgg aagccgagga cgtgggcgtg tactactgca tgcaggccct gcagacccct 300
[0086] tacacctttg gccagggcac caacctggag atcaag 336
[0087] The nucleotide sequence shown in SEQ ID NO:29 corresponds to the amino acid sequence encoded by SEQ ID NO:27, and the nucleotide sequence shown in SEQ ID NO:19 is as follows:
[0088] caaatcactc taaaggaaag tggtccaact ctcgtgaaac ccacccagac cctgacactg 60
[0089] acctgtacct tctccggcct gtctctgagc acatctggag tctccgtggg ctggatccgg 120
[0090] cagcctcctg gcaaggctcc tgagtggctg gccctgatct actgggacga cgacaagaga 180
[0091] tacagccctt ccctgacatc tagactgtcc atcaccaagg acacctccaa gaaccaagtg 240
[0092] gtgctgacca tgaccaacat ggatcctgtg gataccgcta cctactactg cgcccaccca 300
[0093] cggtactacg gcgactcctc tggctactat tggatctggg gccagggcac catggtgacc 360
[0094] gtgtcctct 369
[0095] The nucleotide sequence shown in SEQ ID NO:30 corresponds to the amino acid sequence encoded by SEQ ID NO:28, and the nucleotide sequence shown in SEQ ID NO:20 is as follows:
[0096] agttatgaac taactcaacc accaagtgtg tccgtgtccc ctggccagac cgctcggatc 60
[0097] acctgttctg gcgacgcct gcctaagcag tacgcctact ggtatcagca gaaaccagga 120
[0098] caagctcctg tggtcgtgat gtacaagacc tccgagagac cttctggcat ccccgaaaga 180
[0099] tttagcggat cctcctctgg cacaacagtg accctgacca tctccggcgt gcaggccgag 240
[0100] gacgaggccg actactactg ccagtctgct gattctagcg gcttctacgt gttcggcacc 300
[0101] ggcacccagg tgaccgtgct g 321
[0102] In a fourth aspect, the present invention provides a nucleic acid construct comprising the polynucleotide.
[0103] Further preferably, the polynucleotide further comprises at least one expression control element operably linked to the polynucleotide, such as a histidine tag, a stop codon, etc.
[0104] In a fifth aspect, the present invention provides an expression vector comprising the nucleic acid construct.
[0105] In a sixth aspect, the present invention provides a transformed cell, comprising the polypeptide as described in the second aspect, the polynucleotide as described in the third aspect, the nucleic acid construct as described in the fourth aspect, or the expression vector as described in the fifth aspect. Optionally, it is a eukaryotic expression vector.
[0106] In the seventh aspect, the present invention provides a pharmaceutical composition comprising a human neutralizing antibody or an antigen-binding fragment thereof that binds to the coronavirus S protein as described in the first aspect above, a polypeptide as described in the second aspect above, a polynucleotide as described in the third aspect above, a nucleic acid construct as described in the fourth aspect above, an expression vector as described in the fifth aspect above, or a transformed cell as described in the sixth aspect above, and a pharmaceutically acceptable carrier and / or excipient.
[0107] Further preferably, the pharmaceutical composition is in the form of a nasal spray, an oral preparation, a suppository or a parenteral preparation.
[0108] Further preferably, the nasal spray is selected from aerosols, sprays and powder sprays.
[0109] Further preferably, the oral preparation is selected from tablets, powders, pills, powders, granules, fine granules, soft / hard capsules, film-coated capsules, pellets, sublingual tablets and ointments.
[0110] Further preferably, the parenteral preparation is a transdermal preparation, an ointment, a plaster, an external liquid, an injectable or pushable preparation.
[0111] In the eighth aspect, the present invention provides a human neutralizing antibody or its antigen-binding fragment that binds to the coronavirus S protein as described in the first aspect above, the polypeptide as described in the second aspect above, the polynucleotide as described in the third aspect above, the nucleic acid construct as described in the fourth aspect above, the expression vector as described in the fifth aspect above, or the transformed cell as described in the sixth aspect above, or the pharmaceutical composition as described in the seventh aspect above for use in the preparation of a drug for preventing, treating, detecting or diagnosing new coronavirus infection.
[0112] Preferably, the novel coronavirus is the original strain of SARS-CoV-2 and / or a variant strain of SARS-CoV-2.
[0113] Further preferably, the SARS-CoV-2 variant strains include Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Lambda (C.37), Kappa (B.1.617.1), Delta (B.1.617.2) and / or Omicron (B.1.1.529) strains.
[0114] Among them, the neutralizing antibodies YB9-258 and YB13-292 have good neutralizing activity against the original strain (WT) and mutant strains of the new coronavirus SARS-CoV-2, Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Lambda (C.37), Kappa (B.1.617.1), Delta (B.1.617.2) and / or Omicron (B.1.1.529).
[0115] The neutralizing antibody YB13-208 has good neutralizing activity against the original strain (WT) and mutant strains of the new coronavirus SARS-CoV-2, Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Lambda (C.37), Kappa (B.1.617.1) and / or Delta (B.1.617.2).
[0116] In the ninth aspect, the present invention provides a method for preventing or treating the new coronavirus, comprising: administering to a subject in need thereof a preventive or therapeutically effective amount of a human neutralizing antibody or its antigen-binding fragment that binds to the coronavirus S protein as described in the first aspect above, a polypeptide as described in the second aspect above, a polynucleotide as described in the third aspect above, a nucleic acid construct as described in the fourth aspect above, an expression vector as described in the fifth aspect above, or a transformed cell as described in the sixth aspect above, or a pharmaceutical composition as described in the seventh aspect above.
[0117] Preferably, the novel coronavirus is the original strain of SARS-CoV-2 and / or a variant strain of SARS-CoV-2.
[0118] Further preferably, the SARS-CoV-2 variant strain is Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Lambda (C.37), Kappa (B.1.617.1), Delta (B.1.617.2) and / or Omicron (B.1.1.529) strain.
[0119] The dosage of the active ingredient of the pharmaceutical composition of the present invention varies depending on the subject of administration, the subject organ, symptoms, the method of administration, etc., and can be determined based on the doctor's judgment in consideration of the type of dosage form, the method of administration, the age and weight of the patient, the patient's symptoms, etc.
[0120] Advantageous Effects
[0121] (1) The neutralizing antibodies YB9-258 and YB13-292 of the present invention have good neutralizing activity against the original strain (WT) of the new coronavirus SARS-CoV-2, the variant strain Alpha (B.1.1.7), the variant strain Beta (B.1.351), the variant strain Delta (B.1.617.2), the variant strain Gamma (P.1), the variant strain Lambda (C.37), the variant strain Omicron (B.1.1.529), etc. The neutralizing antibodies YB9-258 and YB13-292 of the present invention have high neutralizing activity against the true virus and pseudovirus of the highly harmful SARS-CoV-2 variant strain Delta (B.1.617.2) and the variant strain Omicron (B.1.1.529), IC 50 ≤0.04ug / ml; the neutralizing antibody YB13-208 of the present invention has good neutralizing activity against the original strain (WT) of SARS-CoV-2, the variant strain Alpha (B.1.1.7), the variant strain Beta (B.1.351), the variant strain Delta (B.1.617.2), the variant strain Gamma (P.1), the variant strain Kappa (B.1.617.1), the variant strain Delta (B.1.617.2), and the variant strain Lambda (C.37), but has no neutralizing activity against the variant strain Omicron (B.1.1.529) of SARS-CoV-2. The neutralizing antibodies YB9-258, YB13-292 and YB13-208 of the present invention can effectively inhibit the infection of SARS-CoV-2 pseudovirus, and also have good neutralizing activity against the true virus. The neutralizing antibody of the present invention has application value in clinical treatment and prevention of SARS-CoV-2 infection.
[0122] (2) The neutralizing antibodies screened by the present invention have broad-spectrum neutralizing activity and can effectively neutralize SARS-CoV-2 and several highly contagious and harmful SARS-CoV-2 variants, such as the SARS-CoV-2 variant Alpha (B.1.1.7), the SARS-CoV-2 variant Beta (B.1.351), the SARS-CoV-2 variant Delta (B.1.617.2), and the SARS-CoV-2 variant Omicron (B.1.1.529).
[0123] (3) The present invention uses the plasma of patients who have recovered from infection with different new coronavirus variants to obtain candidate antibodies with a high spectrum; using flow sorting and single-cell high-throughput testing technology, compared with traditional methods, the large-scale data obtained from high-throughput scVDJ sequencing (scVDJ-seq) enables us to detect the enrichment of B cell clonal types before in vitro antibody expression, which is fast, efficient and high-throughput. The eukaryotic expression system used in the present invention for stable and efficient expression of antibodies makes the obtained antibodies fully humanized and does not require further humanization treatment.
[0124] (4) The present invention collects plasma from patients who have recovered from infection with different new coronavirus variants. First, B cells are enriched by magnetic beads, and new coronavirus S1-specific single B cells are sorted by flow sorting technology. Single cell library construction, BCR immune group library and high-throughput sequencing of transcriptome are performed using 10× Genomics technology. Through data analysis, we sort and score antibody sequences according to different parameters such as the abundance, frequency, germline genes used, mutation rate, etc. of antibody sequences, and select antibody sequences with potential affinity for batch synthesis and eukaryotic expression purification. Then we use ELISA, SPR and other methods to test the binding ability and affinity of candidate antibodies to S1 proteins of different new coronavirus variants, and explore the neutralization ability of pseudoviruses and real viruses of different new coronavirus variants to ensure that the neutralizing antibodies screened are effective and broad-spectrum.
[0125] (5) The present invention provides a potential new antibody drug for the clinical prevention, treatment and detection of the new coronavirus. BRIEF DESCRIPTION OF THE DRAWINGS
[0126] One or more embodiments are exemplarily described by the pictures in the accompanying drawings, and these exemplary descriptions do not constitute limitations on the embodiments. The special word "exemplary" here means "used as an example, embodiment or illustrative". Any embodiment described as "exemplary" here is not necessarily interpreted as being superior or better than other embodiments.
[0127] Figure 1 The ELISA method used in Example 3 of the present invention is used to analyze the binding activity of neutralizing antibodies to S1 antigens of different original strains and variant strains of the new coronavirus;
[0128] Figure 2 It is a schematic diagram of the affinity constant results of different neutralizing antibodies and S1 antigens of different SARS-CoV-2 virus strains in Example 4 of the present invention;
[0129] Figure 3 It is a schematic diagram of the neutralization effect of the neutralizing antibody of Example 7 of the present invention against different SARS-CoV-2 pseudovirus strains. DETAILED DESCRIPTION
[0130] In order to make the purpose, technical solutions and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention. Unless otherwise expressly stated, throughout the specification and claims, the term "including" or its variations such as "comprising" or "including" will be understood to include the stated elements or components, without excluding other elements or other components.
[0131] In addition, in order to better illustrate the present invention, numerous specific details are provided in the specific embodiments below. It should be understood by those skilled in the art that the present invention can also be implemented without certain specific details. In some embodiments, raw materials, elements, methods, means, etc. well known to those skilled in the art are not described in detail, so as to highlight the main purpose of the present invention.
[0132] Hereinafter, the present invention will be described in detail.
[0133] definition
[0134] When referring to a ligand / receptor, antibody / antigen or other binding pair, "specific" binding refers to determining the presence or absence of the binding reaction of the protein, such as the neutralizing antibody of the present invention, to the SARS-CoV-2 S1 protein in a heterogeneous population of proteins and / or other biological agents. Thus, under the specified conditions, a specific ligand / antigen binds to a specific receptor / antibody and does not bind to other proteins present in the sample in significant amounts.
[0135] The reagents, enzymes, culture media, antibiotics, milk and other chemical materials used in the following examples of the present invention are all commercially available products, for example, the Chromium Single Cell V(D)J Reagent Kits, 10X Genomics) kits are purchased from 10X Genomics.
[0136] The antigens and pseudoviruses in the following examples of the present invention are all commercially available products. For example, RBD antigen or S1 antigen are purchased from Beijing Sino Biological Technology Co., Ltd., wherein:
[0137] The product number of the original strain (WT) S1 antigen is: 40591-V08H, Beijing Sino Biological Science and Technology Co., Ltd.
[0138] The product number of the original strain (WT) RBD antigen is: 40592-V08H, Beijing Sino Biological Science Co., Ltd.
[0139] The product number of the mutant strain Delta S1 antigen is: 40591-V08H23, Beijing Yiqiao Shenzhou Technology Co., Ltd.
[0140] The product number of the mutant strain Delta RBD antigen is: 40592-V08H90, Beijing Yibi Shenzhou Technology Co., Ltd.
[0141] The product number of the mutant strain Beta RBD antigen is: 40592-V08H85, Beijing Yibi Shenzhou Technology Co., Ltd.
[0142] The product number of the mutant strain Beta S1 antigen is: 40591-V08H10, Beijing Yibi Shenzhou Technology Co., Ltd.
[0143] The product number of the mutant strain Omicron RBD antigen is: 40592-V08H121, Beijing Yiqiao Shenzhou Technology Co., Ltd.
[0144] The product number of the mutant strain Omicron S1 antigen is: 40591-V08H41, Beijing Yiqiao Shenzhou Technology Co., Ltd.
[0145] The pseudovirus variant strain Omicron was purchased from Nanjing Novozymes Biotech Co., Ltd., catalog number: DD1768-03.
[0146] The pseudovirus variant strain Delta was purchased from Suzhou Biolong Technology Co., Ltd., item number: BDAA0115.
[0147] The pseudovirus original strain WT was purchased from Nanjing Novozymes Biotech Co., Ltd., catalog number: DD1402-03.
[0148] Some commonly used biological materials, such as competent cells, vectors, helper phages, cells to be transformed, etc., are also commercially available products.
[0149] The antibody numbers in the following embodiments correspond to:
[0150] Antibody YB9-258 has the amino acid sequence of the heavy chain variable region shown in SEQ ID NO:7 and the amino acid sequence of the light chain variable region shown in SEQ ID NO:8.
[0151] Antibody YB13-292 has the amino acid sequence of the heavy chain variable region shown in SEQ ID NO:17 and the amino acid sequence of the light chain variable region shown in SEQ ID NO:18.
[0152] Antibody YB13-208 has the amino acid sequence of the heavy chain variable region shown in SEQ ID NO:27 and the amino acid sequence of the light chain variable region shown in SEQ ID NO:28.
[0153] Example 1: Obtaining antibody sequence information by high-throughput single-cell sequencing
[0154] Blood was collected from patients who recovered from the Delta (B.1.617.2) novel coronavirus variant, and peripheral blood mononuclear cells (PBMCs) were separated from the fresh blood by gradient centrifugation using Ficoll. B cells were separated from PBMCs by magnetic beads, and antigen-binding B cells were enriched. Library construction was then performed in the P2 laboratory according to the kit instructions (ChromiumSingle Cell V(D)J Reagent Kits, 10X Genomics). Sequencing was performed on the BGI sequencing platform, running the MGISEQ-2000RS Sequencing Flow cell kit (BGI). After sequencing, the data was analyzed and antibodies were assembled.
[0155] Example 2 Antibody protein expression and purification
[0156] GenScript was commissioned to express and purify the antibody protein.
[0157] Example 3 ELISA analysis of the binding ability of neutralizing antibodies to SARS-CoV-2 original strain and mutant strain antigens
[0158] Take 50ng of SARS-CoV-2 RBD antigen or SARS-CoV-2 S1 antigen to coat ELISA plate at 4℃ overnight. Wash 3 times with PBST (0.05%). Add 100ul of 5% skim milk powder to each well and block at room temperature for 2h. Wash 3 times with PBST. Neutralizing antibody was gradient diluted with skim milk powder, with a starting concentration of 1.5μg / ml (10nM), and then diluted 5 times in sequence, with a total of 8 concentration gradients, added to the wells, and each concentration gradient was repeated 3 wells. 50ul of primary antibody prepared with skim milk powder to 2ug / ml was added and incubated at room temperature for 1h. Wash 3 times with PBST. Add 50ul of 8000-fold diluted Anti human-FC secondary antibody, incubate at room temperature for 45min, and wash 3 times with PBST. Add 100μl TMB colorimetric solution (abcam), color for 10min, add an equal volume of TMB stop buffer (abcam) to stop color development, and read OD450. Analyze the ability of neutralizing antibodies to bind to the antigens of different SARS-CoV-2 virus strains.
[0159] The results of ELISA test using S1 antigen of different SARS-CoV-2 novel coronavirus strains are as follows Figure 1 The results show that:
[0160] Neutralizing antibodies YB9-258 and YB13-292 have good binding activity with the S1 antigen of the original strain (WT) of the new coronavirus SARS-CoV-2, the S1 antigen of the mutant strain Alpha (B.1.1.7), the S1 antigen of the mutant strain Beta (B.1.351), the S1 antigen of the mutant strain Delta (B.1.617.2), the S1 antigen of the mutant strain Gamma (P.1), the S1 antigen of the mutant strain Lambda (C.37), and the S1 antigen of the mutant strain Omicron (B.1.1.529), showing good broad spectrum.
[0161] Except for the low binding activity to the S1 protein of the SARS-CoV-2 mutant strain Omicron (B.1.1.529), the neutralizing antibody YB13-208 has good binding activity to the S1 antigens of other SARS-CoV-2 strains and has good broad spectrum.
[0162] Example 4 Determination of affinity constants of neutralizing antibodies to the original strain and mutant antigens by SPR method
[0163] The S1 antigen of the original strain (WT) of the new coronavirus SARS-CoV-2, Delta (B.1.617.2) S1 antigen and Omicron (B.1.1.529) S1 antigen were coupled to the CM5 chip respectively, and the antibody protein was diluted with HBS-P buffer. In this case, 19.2μg / ml (128nM) was used as the starting concentration of the antibody, and it was diluted 2-fold in sequence, and 6 concentration gradients were diluted, with the buffer as a control. Each injection lasted 120s, dissociation for 240s, flow rate of 30ul / min, and then regenerated with 10mM PH2.0 Glycine, and the cycle was repeated until all concentration gradient injections were completed. After the program was completed, the analysis program provided by the Biacore T200 (GE) instrument was used for fitting analysis to obtain the results of the neutralizing antibody affinity constant. The results are shown in Tables 1 and Figure 2 The results showed that the neutralizing antibodies YB9-258, YB13-292, and YB13-208 all had high affinity for the SARS-CoV-2 S1 antigen of the original strain (WT), the mutant strain Delta (B.1.617.2), and the mutant strain Omicron (B.1.1.529) of the new coronavirus.
[0164] Table 1 Binding dissociation constants KD (M) of each neutralizing antibody affinity
[0165] .
[0166] Example 5 Prediction of neutralizing antibody binding competitive epitopes using SPR method
[0167] Take a CM5 chip and coat it with SARS-CoV-2 Delta (B.1.617.2) S1 antigen until the response value is 150RU. Neutralizing antibodies are prepared with HBS-P buffer at 200nM, with a loading speed of 10ul / min, a saturation time of 200s, and a regeneration time of 60s. Each antibody is saturated separately first, and the response value at saturation is recorded. When conducting a competition experiment, first saturate one of the antibodies, and then add another antibody, and look at the response value and the trend of the real-time curve to determine the epitope relationship between the two antibodies. If the two antibodies are different epitopes, then when the sample is loaded, the RU values of the two antibodies are the same as the response values when they are saturated separately. If there is epitope competition, when the second antibody is added, the value will decrease. The competition between the two can be seen based on the amount of decrease. The results showed that these neutralizing antibodies were divided into two categories with different epitopes. The neutralizing antibody YB9-258 had the same epitope as the antibody YB13-208, and the neutralizing antibody YB13-292 had different epitopes from YB9-258 and YB13-208, indicating that the neutralizing antibody YB13-292 can be used in combination with the neutralizing antibody YB9-258 or YB13-208.
[0168] Example 6 Using the COVID-19 pseudovirus experiment to detect the neutralizing effect of antibodies
[0169] The serum to be tested was inactivated in a 56°C water bath for 30 minutes, centrifuged at 6000g for 3 minutes, and the supernatant was transferred to a 2.5ml centrifuge tube for use. 120μl / well of DMEM serum-free medium was added to B11-D11 (cell control CC, see Table 2); 60μl / well of DMEM serum-free medium was added to E11-G11 (virus control VC, see Table 2); 84uL / well of DMEM serum-free medium was added to G2-G10; 60uL / well of DMEM serum-free medium was added to B2-F10; serum was diluted from 30 times, and serum sample 1 (6μl) was added to G2, G3 and G4 wells... and so on, serum sample 4 (6μl) was added to G8, G9 and G10 wells. Each serum sample was diluted 3 times. Adjust the multichannel pipette to 30 μl, gently pipette and aspirate the liquid in wells G2 to G4 6 to 8 times to mix thoroughly, then transfer 30 μl of liquid to the corresponding wells F2 to F4, gently pipette and aspirate 6 to 8 times and transfer to wells E2 to E4, and so on, finally aspirate and discard 30 μl of liquid from wells B2 to B4, refer to the table for the order of adding samples, and follow the same method for other samples on the plate. Dilute the pseudovirus to 1.3×10 4 (1×104 ~2×10 4 )TCID50 / ml, add 60μl to the 2nd to 10th columns and E11-G11 (virus control VC, see Table 2) wells, so that the amount of pseudovirus in each well is 650 (500-1000) / well. Place the above 96-well plate in a cell culture incubator (37°C, 5% CO2) and incubate for 1 hour. When the incubation time reaches half an hour, take out the 293T-hACE2 cells (confluence rate reaches 80%-90%) prepared in advance in the incubator. Taking T75 culture flask as an example, discard the culture medium in the flask, add 5 ml PBS buffer to wash the cells, pour off PBS, add 3 ml 0.25% trypsin-EDTA, immerse the cells for digestion for 1 minute, pour off the trypsin, place in the cell culture incubator for digestion for 5 minutes, gently tap the side wall of the culture flask to make the cells fall off, add 10 ml culture medium to neutralize the trypsin, blow several times and transfer to a centrifuge tube, centrifuge at 210g for 5 minutes, pour off the supernatant, resuspend the cells with 10 ml DMEM complete culture medium, count the cells, and dilute the cells to 2×10 with DMEM complete culture medium. 5 Incubate for 1 hour, and transfer 100ul of the sample pseudovirus mixture previously incubated in the transparent plate to the TC-treated white plate using a multichannel pipette. Then add 100μl of cells to each well of the 96-well white plate, so that each well has 2×10 cells. 4 . Gently shake the 96-well plate back and forth and left and right to evenly disperse the cells in the wells, and place the 96-well plate in a cell culture incubator and culture at 37°C, 5% CO2 for 72 hours. After 72 hours, remove the 96-well plate from the cell culture incubator, use a multichannel pipette to aspirate 100μl of supernatant from each loading well, and then add 100μl of luciferase detection reagent, and react at room temperature in the dark for 2 minutes. Calculate the neutralization inhibition rate: Inhibition rate = [1-(mean luminescence intensity of the sample group-mean value of the blank control CC) / (mean luminescence intensity VC of the negative group-mean value of the blank control CC)]×100%. Based on the neutralization inhibition rate results, the Reed-Muench method was used to calculate the IC 50 .
[0170] The experimental results using the SARS-CoV-2 original strain (WT) pseudovirus, the variant Delta pseudovirus, and the variant Omicron pseudovirus are as follows Figure 3 As shown, the neutralizing antibodies YB9-258 and YB13-292 have neutralizing activity against the original strain (WT), the variant strain Delta and the variant strain Omicron pseudovirus, while the neutralizing antibody YB13-208 has no neutralizing activity or low neutralizing activity against the SARS-CoV-2 variant strain Omicron pseudovirus. The neutralizing antibodies YB9-258 and YB13-292 have high neutralizing activity against the SARS-CoV-2 variant strain Omicron pseudovirus, IC50 Less than 0.04ug / ml, indicating that they have a higher ability to inhibit the Omicron (B.1.1.529) variant strain from infecting target cells.
[0171] Example 7 Neutralization of antibodies against different true virus strains
[0172] The Guangdong Provincial Center for Disease Control and Prevention was commissioned to conduct neutralizing activity testing of neutralizing antibodies, including the original strain (WT), the mutant strain Delta (B.1.617.2) and the mutant strain Omicron (B.1.1.529) of the real virus. The results are shown in Table 2.
[0173] Table 2 shows that neutralizing antibodies YB9-258 and YB13-292 showed strong neutralizing ability against the original strain (WT), variant strain Delta (B.1.617.2) and variant strain Omicron (B.1.1.529) of SARS-CoV-2, and neutralizing antibody YB13-208 showed strong neutralizing ability against the original strain (WT) and Delta (B.1.617.2) of SARS-CoV-2, but had no neutralizing ability against the variant strain Omicron (B.1.1.529) of SARS-CoV-2. The results in Table 2 also show that the neutralizing activity of neutralizing antibodies with pseudoviruses and with real viruses is well correlated.
[0174] Table 2 Neutralization effect of each neutralizing antibody on different true viruses
[0175]
[0176] In summary, the neutralizing antibodies YB9-258, YB13-292, and YB13-208 can be used as neutralizing antibodies with high neutralizing activity against the new coronavirus (SARS-CoV-2). Among them, the neutralizing antibodies YB9-258 and YB13-292 have excellent broad-spectrum activity, and the neutralizing antibody YB13-208 also has good broad-spectrum activity.
[0177] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or make equivalent replacements for some of the technical features therein. However, these modifications or replacements do not deviate the essence of the corresponding technical solutions from the spirit and scope of the technical solutions of the embodiments of the present invention.
Claims
1. A humanized neutralizing antibody or an antigen-binding fragment thereof that binds to the S protein of the novel coronavirus SARS-CoV-2, comprising a heavy chain variable region and a light chain variable region, The heavy chain variable region comprises: HCDR1 having an amino acid sequence as shown in SEQ ID NO: 1, HCDR2 having an amino acid sequence as shown in SEQ ID NO: 2, and HCDR3 having an amino acid sequence as shown in SEQ ID NO: 3; The light chain variable region comprises: LCDR1 having an amino acid sequence as shown in SEQ ID NO:4, LCDR2 having an amino acid sequence as shown in SEQ ID NO:5, and LCDR3 having an amino acid sequence as shown in SEQ ID NO:
6.
2. The humanized neutralizing antibody or antigen-binding fragment thereof according to claim 1, characterized in that: It contains the heavy chain variable region and the light chain variable region: The heavy chain variable region comprises the amino acid sequence as shown in SEQ ID NO:7, or an amino acid sequence having at least 97% sequence identity with the amino acid sequence as shown in SEQ ID NO:7; and the light chain variable region comprises the amino acid sequence as shown in SEQ ID NO:8, or an amino acid sequence having at least 97% sequence identity with the amino acid sequence as shown in SEQ ID NO:
8.
3. A human neutralizing antibody or antigen-binding fragment thereof as described in claim 1 or 2, wherein the antigen-binding fragment is selected from Fab, Fab', Fab'-SH, Fv, scFv, F(ab')2.
4. An antibody that binds to the S protein of the new coronavirus SARS-CoV-2, having a heavy chain variable region as shown in SEQ ID NO:7 and a light chain variable region as shown in SEQ ID NO:
8.
5. A polynucleotide encoding the human neutralizing antibody or antigen-binding fragment thereof according to any one of claims 1 to 3.
6. The polynucleotide according to claim 5, characterized in that The polynucleotide is DNA or mRNA; the polynucleotide has a nucleotide sequence as shown in SEQ ID NO:9 and SEQ ID NO:
10.
7. A nucleic acid construct comprising the polynucleotide according to claim 5 or 6. An expression vector comprising the nucleic acid construct according to claim 7 .
9. A transformed cell comprising the antibody of claim 4, or the polynucleotide of claim 5 or 6, or the nucleic acid construct of claim 7, or the expression vector of claim 8.
10. A pharmaceutical composition comprising the human neutralizing antibody or its antigen-binding fragment according to any one of claims 1 to 3, or the antibody according to claim 4, or the polynucleotide according to claim 5 or 6, or the nucleic acid construct according to claim 7, or the expression vector according to claim 8, or the transformed cell according to claim 9, and a pharmaceutically acceptable carrier and / or excipient.
11. The pharmaceutical composition according to claim 10, characterized in that The pharmaceutical composition is a nasal spray, an oral preparation or a suppository.
12. The pharmaceutical composition according to claim 10, characterized in that The pharmaceutical composition is a parenteral preparation.
13. Use of a human neutralizing antibody or an antigen-binding fragment thereof according to any one of claims 1 to 3, or an antibody according to claim 4, or a polynucleotide according to claim 5 or 6, or a nucleic acid construct according to claim 7, or an expression vector according to claim 8, or a transformed cell according to claim 9, or a pharmaceutical composition according to any one of claims 10 to 12 in the preparation of a drug for preventing or treating or detecting or diagnosing novel coronavirus infection; The novel coronavirus is the original strain of SARS-CoV-2 and / or a variant strain of SARS-CoV-2; The SARS-CoV-2 variant strains are Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Lambda (C.37), Delta (B.1.617.2) and / or Omicron (B.1.1.529) strains.
